| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.4M | — | -92.8% |
| R&D Expense | $57.3M | — | +8.0% |
| SG&A Expense | $21.3M | — | +4.7% |
| Operating Income | -$83.4M | — | -787.4% |
| Net Income | -$90.1M | — | -1580.4% |
| EPS (Basic) | -$1.72 | — | -1533.3% |
| EPS (Diluted) | -$1.72 | — | -1533.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15.2M | -55.8% | -88.3% |
| Short-term Investments | $135.3M | -30.8% | -1.8% |
| Accounts Receivable | $10.0M | -61.9% | -44.8% |
| Current Assets | $186.5M | -33.7% | -40.5% |
| Total Assets | $341.9M | -24.5% | -30.4% |
| Current Liabilities | $71.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$76.2M | — | -326.5% |
| Capital Expenditures | $1.2M | — | +20.6% |
| Investing Cash Flow | $70.6M | — | +57.8% |
| Financing Cash Flow | -$13.6M | — | -135.4% |
| Free Cash Flow | -$77.4M | — | -337.5% |
| -33.4% |
| Total Liabilities | $320.8M | -8.4% | +48.0% |
| Stockholders' Equity | $21.1M | -79.5% | -92.3% |